Jonathan Weiss, MD
Pulmonary Disease · Monticello, NYNPI 1417952052
Payments from drug & device makers
Across 162 payments — averaging $153.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$22K
- Mylan Specialty L.p.$369
- Abbott$368
- Novo Nordisk$341
- GSK$319
- Johnson & Johnson$276
- plus $2K from 22 others
What the payments were for
- Travel & lodging$36810%
- Food & beverage$3,31290%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $21,646 |
| Mylan Specialty L.p. | 13 | $369 |
| Abbott | 3 | $368 |
| Novo Nordisk | 8 | $341 |
| GSK | 21 | $319 |
| Johnson & Johnson | 8 | $276 |
| Pfizer | 17 | $260 |
| Boehringer Ingelheim | 13 | $205 |
| Exact Sciences | 10 | $196 |
| AbbVie(2 entities) | 9 | $162 |
| Viatris Specialty LLC | 6 | $114 |
| Amarin Pharma, Inc. | 6 | $101 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Astellas Pharma US Inc | 3 | $60 |
| Lilly USA, LLC | 2 | $52 |
| Bayer | 2 | $43 |
| Dexcom, Inc. | 1 | $43 |
| Verona Pharma, Inc. | 2 | $43 |
| Electromed, Inc. | 2 | $41 |
| Merck | 2 | $39 |
| Amgen | 2 | $31 |
| Insmed, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Novartis | 1 | $21 |
| Grifols USA, LLC | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$309
- RYBELSUS$250
- XARELTO$125
- BREZTRI$125
- Yupelri$125
How this compares
$24,915 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 155 | $177,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $156,668 |
| FarxigaDapagliflozin Propanediol | 106 | $110,972 |
| TrulicityDulaglutide | 54 | $76,468 |
| XareltoRivaroxaban | 93 | $63,525 |
| OzempicSemaglutide | 37 | $53,444 |
| JardianceEmpagliflozin | 37 | $52,685 |
| EntrestoSacubitril/Valsartan | 21 | $34,451 |
| JanuviaSitagliptin Phosphate | 35 | $33,432 |
| NuplazidPimavanserin Tartrate | 15 | $29,117 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $27,279 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $25,890 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $22,437 |
| TradjentaLinagliptin | 19 | $21,884 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $16,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $319 | $206,384220 claims |
| PfizerEliquis, Abrysvo | $260 | $181,459169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $21,646 | $152,966164 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $205 | $87,33467 claims |
| Lilly USA, LLCTrulicity | $52 | $76,46854 claims |
| Johnson & JohnsonXarelto | $276 | $63,52593 claims |
| Novo NordiskOzempic | $341 | $53,44437 claims |
| MerckJanuvia, Janumet Xr | $39 | $46,60951 claims |
| NovartisEntresto | $21 | $34,45121 claims |
| AbbVieSynthroid | $162 | $3,07829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Monticello
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.